Total Artificial Heart

Zimmerman, Hannah; Copeland, Jack G.; Allen, Louise A. Aquila; Smith, Richard

doi:10.1016/b978-1-4160-5225-8.00098-2

Cited by 3 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 The same anticoagulation strategy, including multiple tests and combined anticoagulation and antiaggregant therapies, was used in all patients. 16 Adverse events were defined according to the FDA investigational device exemption trial 10 and have been published. 20 They are essentially the same as those published by INTERMACS.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Experience with more than 100 total artificial heart implants

Copeland

Gustafson

et al. 2012

The Journal of Thoracic and Cardiovascular Surgery

Self Cite

150

121

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

“…The Syn-Cardia TAH-t history, use, sizing, function, indications, and anticoagulation, and our previous results up to 55 implants have been reported. [15][16][17] We present the experience with the SynCardia TAH-t from 1993 to 2009.…”

mentioning

confidence: 99%

Experience with more than 100 total artificial heart implants

Copeland

Gustafson

et al. 2012

The Journal of Thoracic and Cardiovascular Surgery

Self Cite

150

121

View full text Add to dashboard Cite

show abstract

“…Current indications for using a TAH, surgical implantation, management after implantation, and subsequent cardiac transplantation are detailed in many publications [6][7][8][9][10][11][12][13][14][15] (also see Reference 5). Etiologies for cardiac failure in TAH recipients have included a long list of irreversible conditions well-covered in the literature.…”

mentioning

confidence: 99%

“It Works.” Every heart transplant program should have one

Copeland

2022

Journal of Cardiac Surgery

Self Cite

View full text Add to dashboard Cite

The total artificial heart (TAH) provides full biventricular cardiac replacement, pulsatile perfusion at flows of 7-9 L/min at low filling pressures. This allows organs that are failing to recover and for the potential cardiac recipient to become a better transplant candidate. Postimplant patients are mobile and able to go through physical rehabilitation in a hospital or at home. The risks are acceptable as shown by the authors. TAH use in more transplant centers could save lives in many transplant candidates. K E Y W O R D S transplant "Trends and outcomes following total artificial heart (TAH) as a bridge to transplant from the UNOS database" by Coyan et al. reports on 433 total artificial heart bridge to transplant (BTT) patients from 2004 to 2020. This experience was with the SynCardia TAH-t. Coyan et al. found waitlist mortality of 7.4% and that 86.6% of implanted waitlist patients were transplanted. One-year posttransplant survival was 80%. The outcomes are similar to those reported in 2004 in a muti-institutional study that led to FDA approval for the bridge to transplantation in the United States of the Syn-Cardia TAH-t. 1 In the FDA study, 79% of all study TAH recipients were transplanted, and 1-and 5-year survivals posttransplantation How to cite this article: Copeland JG, Copeland H. "It Works." Every heart transplant program should have one.

show abstract

Pulsatile Mechanical Circulation, Physiology, and Pump Technology

Copeland

2020

Mechanical Support for Heart Failure

View full text Add to dashboard Cite

Total Artificial Heart

Cited by 3 publications

References 15 publications

Experience with more than 100 total artificial heart implants

Experience with more than 100 total artificial heart implants

“It Works.” Every heart transplant program should have one

Pulsatile Mechanical Circulation, Physiology, and Pump Technology

Contact Info

Product

Resources

About